ADAMTS13 regulation of VWF multimer distribution in severe COVID‐19
Journal of Thrombosis and Haemostasis2021Vol. 19(8), pp. 1914–1921
Citations Over TimeTop 10% of 2021 papers
Soracha E. Ward, Helen Fogarty, Ellie Karampini, Michelle Lavin, Sonja Schneppenheim, Rita Dittmer, Hannah Morrin, Siobhán Glavey, Clíona Ní Cheallaigh, Colm Bergin, Ignacio Martín‐Loeches, Patrick Mallon, Gerard F. Curley, Ross Baker, Ulrich Budde, Jamie M. O’Sullivan, James S. O’Donnell, Niamh O’Connell, Mary Byrne, Liam Townsend, Natalie McEvoy, Jennifer Clarke, Maria Boylan, Razi Alalqam, Amy P Worrall, Claire Kelly, Eoghan de Barra, Roger J. S. Preston, Dermot Kenny
Abstract
These findings support the hypothesis that SARS-CoV-2 is associated with profound quantitative and qualitative increases in plasma VWF levels, and a multifactorial down-regulation in ADAMTS-13 function. Further studies will be required to determine whether therapeutic interventions to correct ADAMTS-13-VWF multimer dysfunction may be useful in COVID-microvascular thrombosis and angiopathy.
Related Papers
- → Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies(2013)74 cited
- → Characterization of ADAMTS14, a novel member of the ADAMTS metalloproteinase family(2001)31 cited
- → Four Cases of Thrombotic Thrombocytopenic Purpura with Poor Prognsosis Despite Early Diagnosis(2007)
- The Research of A Disintegrin-like and Metalloproteinase with Thrombospondin Type 1 Motifs(2010)
- → ADAMTS13, VWF, and TTP(2001)